# Bay City Capital

> Bay City Capital is a VC fund backing Biotechnology and Health Care. See 104 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: San Francisco, United States
- Total investments: 104
- Last investment: May 2021
- Lead investor: 20%
- Fund size: $500M
- Last fund: Nov 2007
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/baycitycapital
- X (Twitter): https://www.twitter.com/baycitycapital
- Website: http://www.baycitycapital.com

Bay City Capital is a VC fund in San Francisco focused on Biotechnology and Health Care. Bay City Capital LLC (Bay City Capital) was established in 1997 for the purpose of managing investment funds in the life sciences industry. Since that date, they have managed six venture funds representing $1.5 billion in capital invested in over 70 companies. Five of these funds are general life sciences funds, and one is a nutrition andagribusiness sector fund.

## Contacts

5 contacts available for Bay City Capital. Shizune tracks 7 team members at Bay City Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/bay-city-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 46 | 44% |
| Health Care | 45 | 43% |
| Pharmaceutical | 21 | 20% |
| Medical | 19 | 18% |
| Therapeutics | 17 | 16% |

29 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 23 | 22% |
| Series A | 16 | 15% |
| Series C | 16 | 15% |
| Funding Round | 11 | 11% |
| Post-IPO Equity | 7 | 7% |

11 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 56 | 54% |
| Canada | 1 | 1% |
| Denmark | 1 | 1% |
| Iceland | 1 | 1% |
| Ireland | 1 | 1% |

6 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| David Beier | Managing Director | 0 | https://shizune.co/investors/profile/david-beier |
| Fred Gage | Scientific Advisory Board | 0 | https://shizune.co/investors/profile/fred-gage |
| Fred Craves | Managing Director | 5 | https://shizune.co/investors/profile/fred-craves |
| Judy Koh | Managing Director/Chief Financial Officer | 0 | https://shizune.co/investors/profile/judy-koh |
| Lionel Carnot | Managing Director | 6 | https://shizune.co/investors/profile/lionel-carnot |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Oculis | The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME(diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops. | $57M | Series C | May 04, 2021 |  |
| Bridge Medicines | Bridge Medicines is a drug discovery company launched in partnership with Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine, Takeda Pharmaceutical Company Ltd. and healthcare investment firms Bay City Capital and Deerfield Management. Bridge Medicines is a groundbreaking initiative that completes anunbroken, fully funded and professionally staffed path from concept to drug candidate, to develop efficiently and quickly innovative therapeutics for the treatment of human diseases. | $10M |  | Nov 13, 2020 |  |
| Sembiosys Genetics | SemBioSys Genetics Inc., a Canadian biotechnology company, announced today that it has signed a feasibility agreement with Dow AgroSciences LLC, of Indianapolis, Indiana, for the Stratosome(TM) Biologics System and its application to animal health biologics. Under the terms of the agreement, SemBioSys and Dow AgroSciences will engage incollaborative research with the aim of determining if the Stratosome(TM) Biologics System can enable the commercialisation of a Dow AgroSciences plant-made vaccine. Under the terms of the agreement, SemBioSys will receive upfront and milestone payments. Further terms of the agreement were not disclosed. "We believe that our Stratosome(TM) Biologics System, with its economic and functional benefits, makes it an outstanding platform for animal health products. We are extremely pleased to be working with Dow AgroSciences in developing their vaccine," said Andrew Baum, president and CEO of SemBioSys."We are very pleased to be working with SemBioSys in evaluating the Stratosome(TM) technology and its application to plant-made biologics for the animal health industry," stated Butch Mercer, Global Business Leader, Animal Health and Nutrition for Dow AgroSciencesThis is the third funded development agreement announced by SemBioSys in the last six months. In December, SemBioSys announced that it had executed a development agreement with Martek Biosciences Corporation (Nasdaq: MATK) to co- develop value-added specialty oil products (DHA containing safflower oil) with potential pharmaceutical and nutraceutical applications. In February, SemBioSys announced that it had entered into an agreement with Syngenta for access to SemBioSys' proprietary oilbody based Stratosome(TM) Biologics and StratoCapture(TM) Purification Systems for the development of Syngenta's biologic products.About SemBioSys Genetics Inc. (www.sembiosys.com)Calgary, Alberta-based SemBioSys Genetics Inc. is a privately held biotechnology company focused on the development of therapeutic proteins and oils using its proprietary oilbody-based technology - the Stratosome(TM) Biologics System. Spun out of the University of Calgary in 1994, the company's investors include Bay City Capital, Dow AgroSciences Canada, Inc., Ventures West Management Inc., BDC Venture Capital, University Technologies International Inc., RBC Capital Partners and Maurice Moloney Ph.D. scientific founder and chief scientific officer. In addition to these investors, SemBioSys has received repayable contributions of CAD$5.5MM from Technology Partnerships Canada, an agency of Industry Canada, and CAD$4.9MM from AVAC Ltd. SemBioSys has partnerships with Syngenta Participations AG and Martek Biosciences for the use of its Stratosome(TM) technology for the development of therapeutic products. |  |  | Oct 01, 2020 |  |
| Xilio Therapeutics | Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of provenimmuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines.These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatmentXilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer.Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States. | $100.5M | Series B | Mar 02, 2020 |  |
| Imara | Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentiallydisease-modifying treatment for sickle cell disease and beta-thalassemia. IMR-687 is being designed to have a multimodal mechanism of action that acts on red blood cells, white blood cells, adhesion mediators and other cell types. | $63M | Series B | Mar 18, 2019 |  |
| NextCure | NextCure is a biopharmaceutical company focused on discovering and developing next generation immuno-oncology-based drugs. The Company is applying its proprietary platforms and know-how to identify novel and biologically relevant targets and develop first-in-class immunotherapy products. | $93M | Series B | Nov 13, 2018 |  |
| Gossamer Bio | Gossamer Bio is a San Diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. Founded by the former Receptos executive team, Gossamer Bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focuson areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology. | $230M | Series B | Jul 23, 2018 |  |
| KBP Biosciences | KBP is a world-class biotechnology research & development organization dedicated to providing innovative therapies for unmet medical needs. | $76M | Series A | Jan 05, 2018 |  |
| Oculis | The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME(diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops. | $23.3M | Series B | Jan 04, 2018 |  |
| Gritstone bio | Gritstone Oncology is a clinical-stage biotech company developing tumor-specific cancer immunotherapies to fight multiple cancer types. Its approach seeks to generate a therapeutic immune response by leveraging insights into the immune system’s ability to recognize and destroy tumor cells by targeting tumor-specific neoantigens. GritstoneOncology is headquartered in Emeryville, California, with key functions located in Cambridge, Massachusetts, and Pleasanton, California. It was founded in August 2015 and is listed on the Nasdaq Global Select Market under the ticker symbol GRTS. |  |  | Oct 01, 2017 |  |

10 of 104 investments shown.

## Co-investors
- [Aberdare Ventures](https://shizune.co/investors/profile/aberdare-ventures) — VC Fund, 17 deals together
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 11 deals together
- [Canaan Partners](https://shizune.co/investors/profile/canaan-partners) — VC Fund, 9 deals together
- [Novo Holdings](https://shizune.co/investors/profile/novo-a-s) — VC Fund, 9 deals together
- [Alta Partners](https://shizune.co/investors/profile/alta-partners) — VC Fund, 8 deals together
- [Delphi Ventures](https://shizune.co/investors/profile/delphi-ventures) — VC Fund, 8 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## Featured in investor lists
- [Biotech Investors in United States](https://shizune.co/investors/biotech-investors-united-states)
- [Biotech VC Funds in United States](https://shizune.co/investors/biotech-vc-funds-united-states)

## FAQ

### What does Bay City Capital invest in?

Bay City Capital invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series B and Series A stage. Most of the 104 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Bay City Capital?

Public channels for Bay City Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Bay City Capital?

The team at Bay City Capital includes David Beier (Managing Director), Fred Gage (Scientific Advisory Board) and Fred Craves (Managing Director), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co